BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $70 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE